Israel Englander Tcr2 Therapeutics Inc. Transaction History

Millennium Management LLC

  • $199 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$1.0 - $1.62 $108,358 - $175,539
-108,358 Reduced 77.38%
31,683 $48,000
Q4 2022

Feb 14, 2023
SELL
$0.83 - $1.44 $106,313 - $184,448
-128,089 Reduced 47.77%
140,041 $140,000
Q3 2022

Nov 14, 2022
SELL
$1.86 - $3.75 $93,531 - $188,572
-50,286 Reduced 15.79%
268,130 $483,000
Q2 2022

Aug 15, 2022
BUY
$2.11 - $2.94 $461,978 - $643,704
218,947 Added 220.12%
318,416 $923,000
Q1 2022

May 16, 2022
SELL
$2.4 - $4.71 $3.23 Million - $6.34 Million
-1,345,848 Reduced 93.12%
99,469 $275,000
Q4 2021

Feb 14, 2022
BUY
$4.58 - $8.34 $5.3 Million - $9.65 Million
1,156,650 Added 400.69%
1,445,317 $6.74 Million
Q3 2021

Nov 15, 2021
BUY
$8.44 - $18.35 $2.3 Million - $5.01 Million
272,860 Added 1726.2%
288,667 $2.46 Million
Q2 2021

Aug 16, 2021
SELL
$16.41 - $24.71 $2.17 Million - $3.27 Million
-132,536 Reduced 89.34%
15,807 $259,000
Q1 2021

May 17, 2021
SELL
$20.38 - $34.07 $6.86 Million - $11.5 Million
-336,585 Reduced 69.41%
148,343 $3.28 Million
Q4 2020

Feb 16, 2021
SELL
$19.0 - $32.63 $3.35 Million - $5.75 Million
-176,173 Reduced 26.65%
484,928 $15 Million
Q3 2020

Nov 16, 2020
BUY
$13.1 - $20.69 $8.14 Million - $12.9 Million
621,171 Added 1555.65%
661,101 $13.4 Million
Q2 2020

Aug 14, 2020
SELL
$6.51 - $16.85 $202,903 - $525,180
-31,168 Reduced 43.84%
39,930 $613,000
Q1 2020

May 14, 2020
BUY
$6.01 - $16.01 $125,524 - $334,384
20,886 Added 41.6%
71,098 $550,000
Q4 2019

Feb 14, 2020
BUY
$12.17 - $17.88 $611,080 - $897,790
50,212 New
50,212 $717,000
Q3 2019

Nov 14, 2019
SELL
$10.15 - $19.53 $1.44 Million - $2.76 Million
-141,435 Closed
0 $0
Q2 2019

Aug 14, 2019
SELL
$13.64 - $20.97 $1.35 Million - $2.08 Million
-99,203 Reduced 41.22%
141,435 $2.02 Million
Q1 2019

May 14, 2019
BUY
$15.01 - $22.15 $3.61 Million - $5.33 Million
240,638 New
240,638 $4.19 Million

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email